STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol Myers Squibb Announces Dividend

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends

NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2022 to stockholders of record at the close of business on October 7, 2022.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable December 1, 2022, to stockholders of record at the close of business on November 8, 2022.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Media:

media@bms.com

Investors:

investor.relations@bms.com

Source: Bristol Myers Squibb

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#122 Ranked by Market Cap
#4058 Ranked by Stock Gains
#655 Ranked by Dividends

BMY Latest News

Apr 11, 2024
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
Apr 8, 2024
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Apr 8, 2024
Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
Apr 6, 2024
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Apr 6, 2024
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

BMY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.